Paper Details

  1. Home
  2. Paper Details

Gemcitabine for recurrent ovarian cancer - a systematic review and meta-analysis.

Author: BergTobias, NøttrupTrine J, RoedHenrik

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Meta-AnalysisA statistical technique that integrates the results of multiple studies to draw more general conclusions about a particular issue.
Systematic ReviewA review that systematically collects, evaluates, and integrates relevant research to answer a specific research question.

Overview

This study discusses the treatment options for recurrent ovarian cancer, focusing on the use of gemcitabine as a single-agent or combination therapy.
Paper Details　
Original Abstract of the Article :
More than 80 % of women with advanced ovarian cancer relapse either during or after adjuvant therapy. Platinum-sensitive women are rechallenged with a platinum-combination therapy and platinum-resistant women are challenged with non-platinum drugs. Gemcitabine is one of many treatments that can be u...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://doi.org/10.1016/j.ygyno.2019.09.026

データ提供：米国国立医学図書館（NLM）

Gemcitabine for Recurrent Ovarian Cancer: A Review of Treatment Options

Ovarian cancer, a challenging disease, often recurs after initial treatment. This study reviews the use of gemcitabine, a chemotherapy drug, for the treatment of recurrent ovarian cancer. The study provides a comprehensive overview of the evidence regarding gemcitabine's efficacy in treating recurrent ovarian cancer, both as a single agent and in combination therapies.

A Powerful Weapon: Gemcitabine for Recurrent Ovarian Cancer

The study highlights the importance of gemcitabine as a valuable treatment option for recurrent ovarian cancer, particularly for patients who are platinum-resistant. The study also explores the use of gemcitabine in combination therapies, which may offer enhanced treatment outcomes.

Combating Cancer: Improving Treatment Outcomes

The study's findings underscore the importance of continued research and development of new treatment strategies for recurrent ovarian cancer. Gemcitabine's role as a potent chemotherapy agent offers a valuable tool in the fight against this challenging disease.

Dr.Camel's Conclusion

This study provides a thorough review of gemcitabine's use in treating recurrent ovarian cancer. The findings highlight the importance of this drug as a valuable therapeutic option, both as a single agent and in combination therapies.

Date :
  1. Date Completed 2019-12-19
  2. Date Revised 2022-12-07
Further Info :

Pubmed ID

31604664

DOI: Digital Object Identifier

10.1016/j.ygyno.2019.09.026

SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.